Jefferies analyst Faisal Khurshid upgraded Summit Therapeutics plc (NASDAQ: SMMT) from Hold to Buy with a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Hot Upgrades Upgrades